top of page

Lack of diversity in clinical trials: A two-decade analysis

Clinical trials are crucial in advancing medical knowledge and developing effective disease treatments. However, the underrepresentation of minority racial and ethnic groups in these trials has long been challenging. Despite efforts to address this issue, racial disparities persist, perpetuating a biased framework of medical evidence and innovation. The COVID-19 vaccine trials have further highlighted these disparities, with minority populations significantly underrepresented. This article explores a comprehensive study conducted on US clinical trials registered in from 2000 to 2020, shedding light on the state of diversity in trials and exploring how Rubix Life Sciences can contribute to improving diversity and inclusion in clinical research.

The Study’s Findings:

The study analyzed data from over 20,000 US-based clinical trials, focusing on the reporting of race/ethnicity and enrollment trends. The findings revealed that less than 44% of trials reported race/ethnicity data, with minorities remaining underrepresented compared to their population proportions. Despite the modest improvements observed over time, more significant efforts are necessary to bridge the diversity gap in clinical research.

Key Insights from the Study:

  1. Insufficient Reporting: A substantial proportion of clinical trials did not report race/ethnicity data, hindering diversity assessment and obscuring potential disparities in treatment outcomes.

  2. Underrepresentation of Minorities: Minorities, including Black, Hispanic/Latino, Asian, American Indian, and other ethnic groups, were consistently underrepresented in clinical trials, with notable disparities compared to their respective population demographics.

  3. Funding Influence: Industry-funded trials were associated with lower rates of race/ethnicity reporting and lower minority enrollment than government-funded trials. This finding raises concerns about the potential impact on treatment efficacy and access for underrepresented populations.

  4. Temporal Trends: While there has been a modest improvement in race/ethnicity reporting over time, the progress remains insufficient to address the diversity gap fully.

Rubix Life Sciences and the Pursuit of Evolution in Clinical Research Diversity:

Rubix Life Sciences, a pioneering healthcare company, is at the forefront of addressing the diversity gap in clinical trials. By leveraging innovative technologies and strategic partnerships, Rubix LS aims to promote inclusivity, ensuring clinical trials reflect the diverse populations they seek to serve. Recognizing the urgent need for greater diversity in research, Rubix LS is committed to fostering an equitable and inclusive healthcare ecosystem.

Evolving the Innovation of Diverse Patient-Centric Design:

With increasing patient data sets the company can access in near real-time (11.87M with 93.8% diverse rating), Rubix LS is now creating the “Patient X” synthetic engine. The conception of an artificial patient mimic platform marks a monumental stride towards enriching clinical trials’ diverse landscape. With meticulous precision, this innovative platform replicates an expansive array of patient attributes encompassing demographics, genetics, and lifestyles. The strategic deployment of such technology is poised to decisively address the persistent challenge of underrepresentation within conventional clinical trials, particularly affecting marginalized cohorts. Through its controlled and adaptable framework, the synthetic patient mimic platform can revolutionize our capacity for comprehensive and enlightening explorations into medical interventions’ safety, efficacy, and ramifications across heterogeneous populations. As we forge ahead, this pioneering approach holds the potential to catalyze the development of tailored and universally pertinent treatments, underscoring our commitment to fostering equitable healthcare outcomes for all.

With new trials that we will pilot, the Patient X engine will allow us to have 19 variants of clinical design methodologies that we can incorporate while looking at >80% adoption proactively before engaging with sponsors and collaborators on a global level to expand access for all therapeutics.

Diversity and inclusion in clinical trials are essential for achieving equitable healthcare outcomes for all populations. The study discussed in this article highlights the persistent lack of diversity and the urgent need for improvement. By addressing the barriers to diversity and implementing proactive strategies, stakeholders in the healthcare industry, including Rubix Life Sciences, can contribute to more representative clinical trials and advance precision medicine for all.



bottom of page